NASDAQ$TNDM
Tandem Diabetes Care Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Tandem Diabetes' first quarter performance demonstrated strength across all business areas.
Tandem Diabetes Care reported a 25% increase in first-quarter sales to $175.9 million compared to the same period in 2021. Worldwide pump shipments increased by 11% to 28,095 pumps. The company updated its full-year financial guidance, projecting sales between $850 million and $865 million.
- First quarter sales increased 25 percent to $175.9 million compared to the same period of 2021.
- Worldwide pump shipments increased 11 percent to 28,095 pumps compared to the same period of 2021.
- Cash, cash equivalents & short-term investments increased $11.6 million in the first quarter of 2022, reaching $635.4 million as of March 31, 2022.
- The company launched Control-IQ® advanced hybrid closed-loop technology in remaining international geographies.
Headline financials
Revenue & EPS history
Tandem Diabetes · Revenue · Quarterly
$176M
Revenue by segment
Tandem Diabetes · $95.8M total across 1 segment · Q1 2022
- Pump Sales$95.8M—100.0%
Forward guidance
For the year ending December 31, 2022, the Company is updating its financial guidance as follows:Sales are estimated to be in the range of $850 million to $865 million, which represents an annual sales growth of 21 percent to 23 percent compared to 2021.
Tailwinds
- Sales are estimated to be in the range of $850 million to $865 million, which represents an annual sales growth of 21 percent to 23 percent compared to 2021.
- Sales inside the United States of approximately $635 million to $645 million, an increase from the prior guidance of $630 million to $640 million
- Sales outside the United States of approximately $215 million to $220 million
- Gross margin is estimated to be approximately 54 percent
- Adjusted EBITDA is estimated to be in the range of 14 percent to 15 percent of sales
Headwinds
- Non-cash charges included in cost of goods sold and operating expenses are estimated to be approximately $95 million, an increase from the Company’s prior guidance.
- Approximately $80 million non-cash, stock-based compensation expense, compared to the prior guidance of $75 million
- Approximately $15 million depreciation and amortization expense
- Operating loss totaled $15.3 million, or negative 9 percent of sales, compared to $3.2 million, or negative 2 percent of sales.
- Net loss was $14.7 million, compared to $5.0 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
-0.4%
Avg return
Earnings day
-2.2%
Avg return
5 days after
+3.5%
Avg return
30 days after
55%
27 / 49 earnings
Positive
+32.8%
Q4 2025
Best reaction
-63.6%
Q3 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +7.6% | -23.6% | +5.0% | |
| Q4 2025 | +32.8% | +40.4% | +34.0% | |
| Q3 2025 | +22.0% | +35.5% | +56.9% | |
| Q1 2025 | +18.6% | +26.5% | +17.6% | |
| Q4 2024 | -35.2% | -42.0% | -42.6% | |
| Q3 2024 | +0.6% | -5.3% | -9.1% | |
| Q2 2024 | +12.7% | +17.3% | +17.6% | |
| Q1 2024 | +23.5% | +21.5% | +41.5% | |
| Q4 2023 | +6.1% | +22.5% | +28.4% | |
| Q3 2023 | -12.1% | -11.5% | +22.5% | |
| Q2 2023 | +2.8% | -13.4% | -14.3% | |
| Q1 2023 | -2.9% | -13.4% | -35.9% | |
| Q4 2022 | -2.1% | -8.0% | +8.0% | |
| Q3 2022 | -34.3% | -31.5% | -23.7% | |
| Q2 2022 | -14.0% | -11.8% | -34.3% | |
| Q1 2022 | -16.4% | -27.6% | -33.8% | |
| Q4 2021 | -0.3% | +7.6% | +7.6% | |
| Q3 2021 | -4.9% | -2.6% | -4.3% | |
| Q2 2021 | +4.7% | +2.6% | +8.8% | |
| Q1 2021 | -5.6% | -11.9% | -5.8% | |
| Q4 2020 | +3.5% | +4.4% | -10.0% | |
| Q3 2020 | +1.5% | -11.4% | -17.9% | |
| Q2 2020 | +1.8% | +3.0% | +10.1% | |
| Q1 2020 | +7.6% | +13.7% | +11.5% | |
| Q4 2019 | -11.4% | -15.2% | -34.7% | |
| Q3 2019 | -6.5% | -8.0% | +2.2% | |
| Q2 2019 | +2.9% | -1.5% | +14.2% | |
| Q1 2019 | -5.8% | +6.3% | +9.2% | |
| Q4 2018 | +27.9% | +43.2% | +31.8% | |
| Q3 2018 | +6.3% | -2.2% | -2.1% | |
| Q2 2018 | +7.7% | +29.0% | +59.9% | |
| Q1 2018 | +7.9% | +7.7% | +96.4% | |
| Q4 2017 | +23.1% | +25.0% | +57.0% | |
| Q3 2017 | -3.4% | -6.4% | +2.7% | |
| Q2 2017 | -17.3% | -39.4% | +8.7% | |
| Q1 2017 | -11.8% | -10.5% | -22.4% | |
| Q4 2016 | -19.1% | -10.6% | -51.1% | |
| Q3 2016 | -63.6% | -66.9% | -63.2% | |
| Q2 2016 | -13.9% | -18.8% | -8.4% | |
| Q1 2016 | +7.1% | — | — | |
| Q4 2015 | +11.9% | — | — | |
| Q3 2015 | +20.6% | — | — | |
| Q2 2015 | +8.9% | — | — | |
| Q1 2015 | +1.7% | — | — | |
| Q4 2014 | -3.1% | — | — | |
| Q3 2014 | -11.0% | — | — | |
| Q2 2014 | +11.4% | — | — | |
| Q1 2014 | -11.7% | — | — | |
| Q4 2013 | +4.0% | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro